Title: 2015 ACVIM Forum Research Abstract Program Document date: 2015_5_27
ID: 3pnuj5ru_770
Snippet: Client-owned dogs (n = 7) with cough >2 months, thoracic radiographic evidence of airway disease and sterile airway inflammation (>7% non-degenerate neutrophils/eosinophils) on bronchoalveolar lavage (BAL) were enrolled. Dogs received maropitant (2 mg/kg) every 48 hours for 14 days. Study endpoints included client perception of clinical signs (surveys at baseline and 14 days and a visual analogue scale (VAS) at baseline, 7 and 14 days), and objec.....
Document: Client-owned dogs (n = 7) with cough >2 months, thoracic radiographic evidence of airway disease and sterile airway inflammation (>7% non-degenerate neutrophils/eosinophils) on bronchoalveolar lavage (BAL) were enrolled. Dogs received maropitant (2 mg/kg) every 48 hours for 14 days. Study endpoints included client perception of clinical signs (surveys at baseline and 14 days and a visual analogue scale (VAS) at baseline, 7 and 14 days), and objective assessment of BALF % neutrophils and eosinophils (baseline and 14 days). A One-Way Repeated Measures ANOVA (VAS) and Mann Whitney Rank Sum tests (BAL cytology) were used. P < 0.05 was considered significant.
Search related documents:
Co phrase search for related documents- airway disease and bronchoalveolar lavage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- airway disease and clinical sign: 1
- airway disease and objective assessment: 1
- analogue scale and baseline VAS visual analogue scale: 1
- analogue scale and bronchoalveolar lavage: 1
- analogue scale and objective assessment: 1, 2, 3
- analogue scale and study endpoint: 1, 2
- analogue scale and VAS visual analogue scale: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- analogue scale and visual analogue scale: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- BAL bronchoalveolar lavage and BALF neutrophil: 1, 2
- BAL bronchoalveolar lavage and bronchoalveolar lavage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- BAL bronchoalveolar lavage and eosinophil BALF neutrophil: 1
- BAL bronchoalveolar lavage and radiographic evidence: 1, 2
- BAL bronchoalveolar lavage and study endpoint: 1
- BAL cytology and bronchoalveolar lavage: 1, 2, 3, 4, 5, 6, 7, 8
- BALF neutrophil and bronchoalveolar lavage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- BALF neutrophil and eosinophil BALF neutrophil: 1, 2
- baseline VAS visual analogue scale and VAS visual analogue scale: 1
- baseline VAS visual analogue scale and visual analogue scale: 1
Co phrase search for related documents, hyperlinks ordered by date